Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case
- 21 January 2021
- journal article
- research article
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 7 (2) , 115-119
Abstract
Acne fulminans (AF) is a rare, acute, and severe form of acne vulgaris often associated with systemic symptoms. Its treatment is challenging and controversial. We report a case of isotretinoin-induced AF (IIAF) in a 12-year-old boy resistant to traditional therapies (oral steroids and isotretinoin). The patient was successfully treated with adalimumab that can be considered an effective off-label option in the treatment of resistant IIAF in children.Keywords
This publication has 12 references indexed in Scilit:
- Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's DiseaseThe Journal of Pediatrics, 2018
- Anti‐TNF‐α therapy modulates mTORC1 signalling in hidradenitis suppurativaJournal of the European Academy of Dermatology and Venereology, 2018
- Adalimumab as a successful treatment for acne fulminans and bilateral acute sacroiliitis with hip synovitis complicating isotretinoin therapyIndian Journal of Dermatology, Venereology and Leprology, 2018
- Acne Fulminans: Treatment Experience from 26 PatientsDermatology, 2017
- Evidence-based recommendations for the management of acne fulminans and its variantsJournal of the American Academy of Dermatology, 2017
- Acne fulminansAnais Brasileiros de Dermatologia, 2017
- Mechanistic target of rapamycin (mTOR) expression is increased in acne patients' skinExperimental Dermatology, 2015
- Acne fulminans: explosive systemic form of acneJournal of the European Academy of Dermatology and Venereology, 2010
- The treatment of acne fulminans: a review of 25 casesBritish Journal of Dermatology, 1999
- Acne fulminans: Report of clinical findings and treatment of twenty-four patientsJournal of the American Academy of Dermatology, 1993